IBCSG 41-13 TREND

  • A randomized phase II Trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for Primary endocrine responsive breast cancer

  • Study Chair
    Dr. Silvia Dellapasqua, Milan, Italy
    Dr. Marco Colleoni, Milan, Italy

    Statistician
    Dr. P. Kathryn Gray

    Director of the Data Management Center
    Holly Shaw

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    March 28, 2013

    Targeted Accrual
    50 patients

    Final Accrual
    51 patients

    Date of enrollment closure
    January 10, 2017

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login